T3D Therapeutics Selected to Present Topline Results from the Phase 2 PIONEER Study of T3D-959 as Late Breaking News at the 16th Clinical Trials on Alzheimer’s Disease Conference (CTAD)
RESEARCH TRIANGLE PARK, N.C., Oct. 3, 2023 /PRNewswire/ -- T3D Therapeutics, Inc. ("T3D") a clinical stage drug development company engaged in the development of T3D-959, a new orally administered drug intended for the treatment...
T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease
RESEARCH TRIANGLE PARK, N.C., April 20, 2021 / T3D Therapeutics, Inc. ("T3D"), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced today the initiation of dosing...
T3D Therapeutics Receives a Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2020 /PRNewswire/ -- T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced today that it has received...
Alzheimer’s Association Part The Cloud Grant Program Invests $24 Million in 16 Innovative Research Trials
CHICAGO, AUGUST 25, 2020 — The Clinical trials investigating 16 promising therapies for Alzheimer’s and dementia are taking off thanks to $24 million in new grant funding from the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates....
Leading Alzheimer’s Disease Experts Join T3D Therapeutics’ Scientific Advisory Board
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2020 - T3D Therapeutics, Inc. ("T3D" ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced today the formation of a new...
T3D Therapeutics Begins Enrollment in the PIONEER Phase 2 Clinical Trial of T3D-959 in Patients with Mild to Moderate Alzheimer’s Disease
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2020 - T3D Therapeutics, Inc. ("T3D" ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced today the initiation of...
T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer’s Disease.
T3D Therapeutics is now fully funded to initiate the Phase 2 PIONEER Study of T3D-959 in Mild-to-Moderate Alzheimer's Disease Patients RESEARCH TRIANGLE PARK, N.C., Nov. 4, 2019 -- T3D Therapeutics, a clinical stage drug development company engaged in the development...
A New Approach to Treating Alzheimer’s Disease Receives Major NIA Backing
Research Triangle Park, NC, May 20, 2019 — T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959 (the “Company”), a new orally administered treatment for Alzheimer’s disease (AD), announced today that it has received a grant...
T3D Therapeutics Announces Presentation of Final Phase 2a Results of T3D-959 in Mild to Moderate Alzheimer’s Subjects at the 2018 Alzheimer’s Association International Conference
T3D Therapeutics, Inc. today announced that final Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in a session at the 2018 Alzheimer’s Association International Conference (AAIC) entitled ‘Novel Therapeutic Approaches for...
T3D Therapeutics Announces Presentation of Neuroimaging Results From a Phase 2a Trial of T3D-959 in Mild to Moderate Alzheimer’s Subjects at the 20th Annual Meeting of the American Society of Experimental Therapeutics
T3D Therapeutics, Inc. today announced that FDG-PET neuroimaging data from a Phase 2a trial with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in an oral and poster presentation entitled ‘A Neurometabolic Approach to Treating Alzheimer’s...